Axsome Therapeutics (AXSM) COO sells 4,750 shares after option exercise
Rhea-AI Filing Summary
Axsome Therapeutics, Inc. Chief Operating Officer Mark L. Jacobson reported an exercise-and-sell transaction in company stock. He exercised stock options to acquire 4,750 shares of common stock at $12.95 per share, then sold the same 4,750 shares in open-market transactions at weighted average prices of about $227.94 and $228.18.
The footnotes state these options had been held for 7 years and were exercised before their 10-year expiration, and that the sales were made under a pre-approved Rule 10b5-1 plan, which has now been completed. Following the sales, he reports no directly held common shares but continues to hold 114,954 stock options expiring on March 19, 2029.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 4,750 shares ($1.02M approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
Jacobson Mark L.
Role
Chief Operating Officer
Sold
4,750 shs ($1.08M)
Approx. gross sale proceeds
$1.08M
Approx. exercise cost
$62K
Approx. pre-tax spread
$1.02M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 233 | $0.00 | $0.00 |
| Exercise | Common Stock | 233 | $12.95 | $3K |
| Sale | Common Stock | 233 | $228.18 | $53K |
| Exercise | Stock Option (Right to Buy) | 4,517 | $0.00 | $0.00 |
| Exercise | Common Stock | 4,517 | $12.95 | $58K |
| Sale | Common Stock | 4,517 | $227.94 | $1.03M |
Holdings After Transaction:
Stock Option (Right to Buy) — 114,954 shares (Direct);
Common Stock — 0 shares (Direct)
Footnotes (5)
- F1. Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.
- F2. Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.
- F3. Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- F4. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.12 and $231.97.
- F5. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.01 and $230.77.
Key Figures
Shares sold: 4,750 shares
Weighted average sale prices: $227.94 and $228.18 per share
Option exercise price: $12.95 per share
+4 more
7 metrics
Shares sold
4,750 shares
Common stock sold in open-market transactions
Weighted average sale prices
$227.94 and $228.18 per share
Open-market sale prices for common stock
Option exercise price
$12.95 per share
Conversion or exercise price for stock options
Options exercised
4,750 options
Stock options converted into common shares
Remaining stock options
114,954 options
Stock options held after transactions, expiring March 19, 2029
Option expiration date
March 19, 2029
Final expiration for the reported stock option grant
Sale price ranges
$225.01–$231.97 per share
Ranges for series of open-market sale transactions
Key Terms
Rule 10b5-1 plan, stock options, open market transactions, weighted average sale price, +1 more
5 terms
Rule 10b5-1 plan financial
"Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
stock options financial
"Represents an exercise of stock options which were held for 7 years"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
open market transactions financial
"Represents the weighted average sale price of a series of open market transactions"
Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.
weighted average sale price financial
"Represents the weighted average sale price of a series of open market transactions"
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Axsome Therapeutics (AXSM) report for Mark L. Jacobson?
Axsome Therapeutics reported that COO Mark L. Jacobson exercised options for 4,750 common shares at $12.95 per share and sold all 4,750 shares in open-market trades around $228 per share, according to the Form 4 filing and related footnotes.
Were the recent AXSM insider stock sales by the COO under a 10b5-1 plan?
Yes. The filing footnotes state the transactions were executed under a pre-approved Rule 10b5-1 trading plan. This type of plan pre-schedules trades, indicating the timing was planned rather than discretionary. The footnote also notes that this particular plan has now been completed.
What stock options did the Axsome Therapeutics COO exercise in this Form 4 filing?
He exercised stock options covering 4,750 shares of common stock at a conversion or exercise price of $12.95 per share. The options were originally granted with a March 19, 2029 expiration date and had been held for approximately seven years before exercise, according to the footnotes.